Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Pathway enrichment analysis of co-DEGs of COVID-19, COPD and PA_
| Database type | Pathways | p-values | Genes |
|---|---|---|---|
| KEGG | Focal adhesion | 5.21E-03 | TNXB/PGF |
| Ras signaling pathway | 6.88E-03 | RALBP1/PGF | |
| PI3K-Akt signaling pathway | 1.55E-02 | TNXB/PGF | |
| Pathways in cancer | 3.30E-02 | RALBP1/PGF | |
| Pancreatic cancer | 4.10E-02 | RALBP1 | |
| ECM-receptor interaction | 4.74E-02 | TNXB | |
| NOD-like receptor signaling pathway | 9.52E-02 | GBP3 | |
| Axon guidance | 9.57E-02 | ABLIM3 | |
| Rap1 signaling pathway | 1.10E-01 | PGF | |
| MAPK signaling pathway | 1.50E-01 | PGF | |
| WikiPathways | Focal Adhesion WP306 | 5.06E-03 | TNXB/PGF |
| RalA downstream regulated genes WP2290 | 6.58E-03 | RALBP1 | |
| Estrogen metabolism WP697 | 9.86E-03 | ARSE | |
| Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932 | 1.15E-02 | TNXB/PGF | |
| miRNA targets in ECM and membrane receptors WP2911 | 1.20E-02 | TNXB | |
| PI3K-Akt signaling pathway WP4172 | 1.43E-02 | TNXB/PGF | |
| VEGFA-VEGFR2 Signaling Pathway WP3888 | 2.25E-02 | TNXB/PGF | |
| Hematopoietic Stem Cell Differentiation WP2849 | 2.98E-02 | TNXB | |
| Pancreatic adenocarcinoma pathway WP4263 | 4.79E-02 | RALBP1 | |
| Integrin-mediated Cell Adhesion WP185 | 5.42E-02 | TNS1 | |
| BioCarta | Ras Signaling Pathway Homo sapiens h rasPathway | 1.09E-03 | RALBP1 |
| ADP-Ribosylation Factor Homo sapiens h arapPathway | 1.58E-03 | RALBP1 | |
| Erk and PI-3 Kinase Are Necessary for Collagen Binding in Corneal Epithelia Homo sapiens h ecmPathway | 1.69E-02 | TNS1 | |
| Rho cell motility signaling pathway Homo sapiens h rhoPathway | 1.75E-02 | RALBP1 | |
| Integrin Signaling Pathway Homo sapiens h integrinPathway | 1.80E-02 | TNS1 | |
| Rac 1 cell motility signaling pathway Homo sapiens h rac1Pathway | 1.96E-02 | RALBP1 | |
| T Cell Receptor Signaling Pathway Homo sapiens h TCR pathway | 2.98E-02 | RALBP1 | |
| Reactome | VEGF ligand-receptor interactions Homo sapiens R-HSA-194313 | 4.39E-03 | PGF |
| Homo sapiens R-HSA-195399 | 4.39E-03 | PGF | |
| The activation of arylsulfatases Homo sapiens R-HSA-1663150 | 7.13E-03 | ARSE | |
| DCC mediated attractive signaling Homo sapiens R-HSA-418885 | 7.67E-03 | ABLIM3 | |
| Gamma carboxylation, hypusine formation and arylsulfatase activation Homo sapiens R-HSA-163841 | 2.12E-02 | ARSE | |
| Glycosphingolipid metabolism Homo sapiens R-HSA-1660662 | 2.23E-02 | ARSE | |
| Netrin-1 signaling Homo sapiens R-HSA-373752 | 2.29E-02 | ABLIM3 | |
| ECM proteoglycans Homo sapiens R-HSA-3000178 | 2.98E-02 | TNXB | |
| Sphingolipid metabolism Homo sapiens R-HSA-428157 | 4.00E-02 | ARSE | |
| Interferon gamma signaling Homo sapiens R-HSA-877300 | 5.00E-02 | GBP3 |
GO study of COVID-19, COPD, and PAH co-DEGs_
| Category | GO ID | Term | p-values | Genes |
|---|---|---|---|---|
| GO-BP | GO: 0060754 | positive regulation of mast cell chemotaxis | 2.75E-03 | PGF |
| GO: 0060753 | regulation of mast cell chemotaxis | 3.30E-03 | PGF | |
| GO: 0032489 | regulation of Cdc42 protein signal transduction | 4.39E-03 | RALBP1 | |
| GO: 0048251 | elastic fiber assembly | 4.39E-03 | TNXB | |
| GO: 0031401 | positive regulation of protein modification process | 5.88E-03 | RALBP1/PGF | |
| GO: 0030042 | actin filament depolymerization | 6.03E-03 | MICAL3 | |
| GO: 0050930 | induction of positive chemotaxis | 6.03E-03 | PGF | |
| GO: 0038084 | vascular endothelial growth factor signaling pathway | 7.67E-03 | PGF | |
| GO: 0042327 | positive regulation of phosphorylation | 8.13E-03 | RALBP1/PGF | |
| GO: 0001932 | regulation of protein phosphorylation | 8.95E-03 | RALBP1/PGF | |
| GO-CC | GO: 0015629 | actin cytoskeleton | 1.61E-01 | ABLIM3 |
| GO: 0062023 | collagen-containing extracellular matrix | 1.90E-01 | TNXB | |
| GO: 0005925 | focal adhesion | 1.93E-01 | TNS1 | |
| GO: 0030055 | cell-substrate junction | 1.97E-01 | TNS1 | |
| GO: 0005856 | cytoskeleton | 2.85E-01 | ABLIM3 | |
| GO:0005634 | nucleus | 7.44E-01 | SP140/MICAL3 | |
| GO:0043231 | intracellular membrane-bounded organelle | 8.22E-01 | SP140/MICAL3 | |
| GO-MF | GO: 0005172 | vascular endothelial growth factor receptor binding | 6.58E-03 | PGF |
| GO: 0071949 | FAD binding | 1.37E-02 | MICAL3 | |
| GO: 0042056 | chemoattractant activity | 1.75E-02 | PGF | |
| GO: 0016709 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen | 1.95E-02 | MICAL3 | |
| GO: 0050660 | flavin adenine dinucleotide binding | 2.98E-02 | MICAL3 | |
| GO: 0004867 | serine-type endopeptidase inhibitor activity | 3.25E-02 | TFPI2 | |
| GO: 0008083 | growth factor activity | 4.68E-02 | PGF | |
| GO: 0070851 | growth factor receptor binding | 5.63E-02 | PGF | |
| GO: 0005126 | cytokine receptor binding | 5.63E-02 | PGF | |
| GO: 0004866 | endopeptidase inhibitor activity | 6.15E-02 | TFPI2 |
Recommended drugs for COVID-19, COPD, PAH_
| Name | p-value | Chemical formula | Structure |
|---|---|---|---|
| Acetaminophen CTD 00005295 | 2.40E-03 | C8H9NO2 | |
| dmnq CTD 00002569 | 3.21E-03 | C12H10O4 | |
| 2,2’,4,4’,5,5’-hexachlorobiphenyl CTD 00000731 | 5.57E-03 | C12H4Cl6 | |
| Hexylene glycol TTD 00008431 | 6.58E-03 | C6H14O2 | |
| Tetradioxin CTD 00006848 | 8.61E-03 | C12H4Cl4O2 | |
| Bisindolylmaleimide IV CTD 00003116 | 9.31E-03 | C20H13N3O2 | |
| Leukotriene C4 CTD 00007223 | 9.31E-03 | C30H47N3O9S | |
| Azacyclonol HL60 UP | 9.55E-03 | C18H21NO | |
| Corbadrine PC3 UP | 1.26E-02 | C9H13NO3 | |
| Mecamylamine CTD 00006250 | 1.48E-02 | C11H21N |